Janssen Pharma (JNJ) Plans to Gain FDA Approval for 10 New Products by 2019

Go back to Janssen Pharma (JNJ) Plans to Gain FDA Approval for 10 New Products by 2019

Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue

May 20, 2015 7:30 AM EDT

NEW BRUNSWICK, N.J., May 20, 2015 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) will announce plans to file for regulatory approval of more than 10 new products between 2015 and 2019, each with the potential to exceed $1 billion in revenue1, as well as more than 40 line extensions of existing and new medicines.

With a portfolio focused on five core therapeutic areas Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism and Oncology the Pharmaceutical segment of Johnson & Johnson (NYSE: JNJ) is delivering transformational new... More